AbbVie's JAK inhibitor Rinvoq, Phase III clinically demonstrated the potential for the treatment of endeavoid dermatitis.

In the Phase III Measure Up 1 study, patients treated with 15 mg or 30 mg doses of Rinvoq improved their eczema area severity index (EASI 75) by 75 percent at the 16th week, respectively, compared with 16 percent in the placebo group.
In addition, 48% and 62% of patients treated at 15 mg or 30 mg doses of Rinvoq were assessed as clear or almost clear (0/1) by the global assessment of isoside dermatitis (vIGA-AD) at the 16th week, respectively, while the placebo group was 8%.
patients who took the Rinvoq dose of 15 mg/30 mg at week 16 had 52%/60% itching improvement, respectively, while the placebo group had 12%.
Compared to receiving a placebo, patients with Rinvoq 30 mg observed a decrease in itching on the first day after taking the first dose (12 percent to 4 percent, respectively), and patients taking a 15 mg dose observed an improvement in itching two days after taking the first dose (16 percent to 3 percent).
Rinvoq was approved in the United States last year to treat rheumatoid arthritis.
Phase III trial of Rinvoq's treatment of endexual dermatitis, rheumatoid arthritis, psoriasis arthritis, axon spinal arthritis, Crohn's disease, ulcerative colitis and cytocytoarthritis is under way.
.